Characterizing clinically recognized hypertrophic cardiomyopathy in six European countries using real-world data [0.03%]
使用真实世界数据描述六个国家临床确诊的肥厚型心肌病特征
Marta Alcalde-Herraiz,Antonella Delmestri,Hezekiah Omulo et al.
Marta Alcalde-Herraiz et al.
Background and aims: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. However, large-scale epidemiological evidence remains scarce due to challenges in real-world disease recognition. This st...
Observational Study
ESC heart failure. 2026 Aug 27;13(5):xvag218. DOI:10.1093/eschf/xvag218 2026
Distinct prognostic trajectories of heart failure phenotypes following kidney transplantation [0.03%]
肾移植后不同类型心力衰竭的预后轨迹各不相同
Maor Bril,Ashraf Imam,Elchanan Parnasa et al.
Maor Bril et al.
Background and aims: Heart failure (HF) drives post-kidney transplant (KT) morbidity. While KT reverses components of uraemic cardiomyopathy, the persistence of post-transplant risk in HF with preserved (HFpEF) versus HF ...
Timing-specific factors associated with early, intermediate, and late readmission after heart failure hospitalization [0.03%]
与心力衰竭住院后早期、中期和晚期再入院相关的特定时间因素
Gen Li,Zhanyue Shi,Tengfei Gu et al.
Gen Li et al.
Aims: To identify factors associated with early, intermediate, and late readmission after heart failure hospitalization. Methods and results: ...
Parity and heart failure risk in diabetic women with coronary artery disease: a multicentre cohort study [0.03%]
糖尿病女性冠心病患者的心力衰竭风险与性别差异:多中心队列研究
Yuko Fujita,Takeshi Morimoto,Koichi Node et al.
Yuko Fujita et al.
Introduction: Women with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) face elevated heart failure (HF) risk compared with men. Although population-based studies have linked parity to cardiovascular ou...
Multicenter Study
ESC heart failure. 2026 Aug 27;13(5):xvag206. DOI:10.1093/eschf/xvag206 2026
Differential Rates of Guideline-Directed Medical Therapy Modification in C-MIC and Control Patients: Results from the C-MIC II Trial [0.03%]
C-MIC和对照患者中指南指导的药物治疗修改速度的不同:C-MIC II试验结果
Marat Fudim,Tamara Kovacevic-Preradovic,Dragana N Kosevic et al.
Marat Fudim et al.
Background: In the C-MIC II trial, C-MIC therapy improved outcomes in patients with heart failure (HF) with reduced ejection fraction (HFrEF). We evaluated whether differences in background HF medication adjustments influ...
Jeroen Dauw,Guillaume Baudry,Marta Cobo Marcos et al.
Jeroen Dauw et al.
Managing cardiorenal syndrome in acute decompensated heart failure remains a major challenge in contemporary cardiology. While pharmacological decongestion with diuretics is the cornerstone of therapy and is effective in most patients, wors...
Type 2 diabetes in heart failure with preserved and mildly reduced ejection fraction: insights from the REDUCE-LAP-HF II trial [0.03%]
II期REDUCE-LAP-HF试验中射血分数保留和轻度降低的心力衰竭合并2型糖尿病患者的预后特征
Misha Dagan,Shane Nanayakkara,Anna L Beale et al.
Misha Dagan et al.
Background and aims: Type 2 diabetes mellitus (T2DM) and obesity are the archetypal components of cardiometabolic syndromes associated with heart failure (HF) with preserved or mildly reduced ejection fraction (HFpEF/HFmr...
Randomized Controlled Trial
ESC heart failure. 2026 Jul 4;13(4):xvag210. DOI:10.1093/eschf/xvag210 2026
Practices and barriers in screening for Cognitive Impairment in Heart Failure: a Clinician Survey [0.03%]
心力衰竭认知障碍筛查现状及障碍因素调查——基于临床医师的调研分析
Sotiria Liori,Chris Kapelios,Kalliopi Keramida et al.
Sotiria Liori et al.
Background: Cognitive impairment (CI) affects a significant percentage of heart failure (HF) patients, reducing adherence and worsening outcomes. Routine cognitive assessment remains limited. ...